CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Study Number

1195721

Phase

Age Group

Adult

Principal Investigator

Grace Dy

Purpose

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

Check your eligibility for this trial

Check now

Full Title

A PHASE 2 STUDY OF Mecbotamab Vedotin (CA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHO HAD PRIOR DISEASE PROGRESSION ON or are Intolerant to a PD-1/L1, EGFR, OR ALK INHIBITOR

ClinicalTrials.Gov ID

NCT04681131

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.